Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The overall response rate was 44.7% after a median follow-up of 15 months.
The median overall survival was not reached at 3 years.
The 7-year survival results were superior with MATRIX.
The 3-year overall survival rate was 95% with one regimen and 100% with the other.
Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.
Six patients experienced a grade 5 treatment-related adverse event.
Researchers sought to determine whether adding bortezomib to bendamustine-rituximab induction therapy would improve survival in patients with mantle cell lymphoma.
Researchers sought to determine whether a combination therapy of romidepsin and lenalidomide would be effective as initial therapy for patients with PTCL.
Researchers sought to determine whether penpulimab would have efficacy and a low rate of serious AEs in patients with relapsed/refractory classic Hodgkin lymphoma.
Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.
The open-label, phase 3 KEYNOTE-204 trial randomly assigned 304 patients with relapsed/refractory cHL to receive pembrolizumab or BV.
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Radiation therapy alone was highly effective for the treatment of Helicobacter pylori–independent gastric mucosa-associated lymphoid tissue lymphoma.
Zanubrutinib is marketed under the trade name Brukinsa and is currently indicated for the treatment of mantle cell lymphoma.
Researchers sought to determine whether combining nivolumab with brentuximab vedotin would be safe and effective in treating patients with mediastinal gray zone lymphoma.
Researchers sought to determine the recommended dose, safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib in patients with symptomatic untreated CLL.
TCI use also resulted in an increased risk of lymphoma in the 3 studies with topical corticosteroid comparators.